Marangolo M, Rosti G, Amadori D, Leoni M, Ardizzone A, Fiorentini G, Cruciani G, Tienghi A, Ravaioli A, Sebastiani L
Medical Oncology Unit, City Hospital, Ravenna, Italy.
Bone Marrow Transplant. 1989 Jul;4(4):405-8.
A pilot study was conducted in which 15 patients with small cell lung cancer (SCLC) with limited or extended disease were treated with high dose etoposide (600 mg/m2 daily for 3 consecutive days) followed by autologous bone marrow transplantation (ABMT). Twelve patients underwent a double graft. All had achieved complete or partial remission with conventional induction chemotherapy (adriamycin and etoposide, plus cisplatin in five cases). After ABMT six of the 15 patients did not receive radiotherapy to the chest; all but four patients received prophylactic brain irradiation. No toxic deaths were recorded during the period of aplasia. Eleven patients relapsed and died after ABMT. The median time to death was 18 months. One other patient died at 13 months of unknown cause. At the present time three patients are alive and free of disease at 54, 51 and 47 months respectively. This pilot study shows that high dose etoposide and ABMT is well tolerated as late intensification for responsive SCLC. Definite conclusions about its precise role in therapy cannot yet be drawn.
进行了一项试点研究，15例局限期或广泛期小细胞肺癌（SCLC）患者接受了高剂量依托泊苷治疗（连续3天，每日600mg/m²），随后进行自体骨髓移植（ABMT）。12例患者接受了双重移植。所有患者均通过传统诱导化疗（阿霉素和依托泊苷，5例加用顺铂）实现了完全或部分缓解。ABMT后，15例患者中有6例未接受胸部放疗；除4例患者外，其余患者均接受了预防性脑照射。再生障碍期未记录到毒性死亡病例。11例患者在ABMT后复发并死亡。中位死亡时间为18个月。另1例患者在13个月时因不明原因死亡。目前，3例患者分别在54、51和47个月时存活且无疾病。这项试点研究表明，高剂量依托泊苷和ABMT作为对反应性SCLC的晚期强化治疗耐受性良好。关于其在治疗中的确切作用尚未得出明确结论。
